BREAKTHROUGH THERAPIES IN TYPE 2 DIABETES: ADVANCED ROLE OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS

Type 2 diabetes mellitus (T2DM) is a global health challenge characterized by chronic hyperglycemia and associated complications. Recent therapeutic breakthroughs, particularly GLP-1 receptor agonists and SGLT2 inhibitors, have transformed diabetes management. These agents not only reduce blood glucose levels but also provide cardiovascular and renal protection. This article provides a comprehensive review of their mechanisms, clinical efficacy, combination therapy, and future perspectives in modern diabetes care.